ARTICLE | Politics, Policy & Law
Goodwill hunting
Commentary: Individual companies, not BIO, PhRMA, must address Turing outcry
September 28, 2015 7:00 AM UTC
Martin Shkreli and Hillary Clinton last week provided the flint and steel that ignited a dry tinderbox of well-worn ideas about controlling drug prices.
Like all wildfires, the furor flared in the blink of an eye, even by the standards of today's hyperkinetic, Twitter-driven news cycle. Shkreli and his Turing Pharmaceuticals AG were called to account by The New York Times on Sunday for increasing the price of Daraprim pyrimethamine by more than fiftyfold. Clinton rushed in on Monday to fan the flames with a populist crusader's call for reforms, which she issued on Tuesday. ...